BR112021018817A2 - Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade - Google Patents

Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade

Info

Publication number
BR112021018817A2
BR112021018817A2 BR112021018817A BR112021018817A BR112021018817A2 BR 112021018817 A2 BR112021018817 A2 BR 112021018817A2 BR 112021018817 A BR112021018817 A BR 112021018817A BR 112021018817 A BR112021018817 A BR 112021018817A BR 112021018817 A2 BR112021018817 A2 BR 112021018817A2
Authority
BR
Brazil
Prior art keywords
formulation
weight
peptides
proteins
small molecules
Prior art date
Application number
BR112021018817A
Other languages
English (en)
Inventor
Aurélia Galus
Benoit Hilbold
Julien Meissonnier
Thomas Pointeaux
Vincent Plassat
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of BR112021018817A2 publication Critical patent/BR112021018817A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade. a presente invenção refere-se a uma divulgação dirigida para uma formulação farmacêutica, destinada à distribuição oral de moléculas pouco permeáveis sintéticas ou naturais, ou sais/solvatos das mesmas tendo uma atividade terapêutica. a formulação farmacêutica pode incluir uma molécula pouco permeável sintética ou natural, ou sal ou solvato da mesma em uma quantidade de 0,01-10 % em peso do peso total da formulação; uma fase lipofílica compreendendo triglicerídeos de ácidos graxos em uma quantidade de 50-80 % em peso do peso total da formulação; e pelo menos um tensoativo lipofílico compreendendo ésteres parciais de poliol e ácidos graxos, em uma quantidade de cerca de 10-50 % em peso do peso total da formulação.
BR112021018817A 2019-04-11 2020-04-10 Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade BR112021018817A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832508P 2019-04-11 2019-04-11
PCT/US2020/027801 WO2020210723A1 (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Publications (1)

Publication Number Publication Date
BR112021018817A2 true BR112021018817A2 (pt) 2021-11-23

Family

ID=70476554

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021020287A BR112021020287A2 (pt) 2019-04-11 2020-04-10 Formulação para distribuição oral de proteínas, peptídeos e pequenas moléculas com pouca permeabilidade
BR112021018817A BR112021018817A2 (pt) 2019-04-11 2020-04-10 Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021020287A BR112021020287A2 (pt) 2019-04-11 2020-04-10 Formulação para distribuição oral de proteínas, peptídeos e pequenas moléculas com pouca permeabilidade

Country Status (16)

Country Link
US (3) US20220249468A1 (pt)
EP (2) EP3952899A1 (pt)
JP (2) JP2022526833A (pt)
KR (2) KR20210151185A (pt)
CN (2) CN113784722A (pt)
AR (1) AR118654A1 (pt)
AU (2) AU2020272059A1 (pt)
BR (2) BR112021020287A2 (pt)
CA (2) CA3134550A1 (pt)
CO (2) CO2021012462A2 (pt)
EA (2) EA202192792A1 (pt)
IL (2) IL287084A (pt)
MX (2) MX2021012354A (pt)
SG (2) SG11202111251SA (pt)
WO (2) WO2020210723A1 (pt)
ZA (1) ZA202108909B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
EP0684834A4 (en) * 1993-02-17 1996-09-25 Smithkline Beecham Corp MICROEMULSIONS CONTAINING THERAPEUTIC PEPTIDES.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
CZ20032225A3 (cs) 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
WO2003047493A2 (en) * 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
CA2487976C (en) 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
CN101048137A (zh) * 2004-10-29 2007-10-03 诺瓦提斯公司 可自发分散的药物组合物
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
CN105688191A (zh) * 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
KR20100058550A (ko) * 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 녹농균 감염 치료시 치료제로서의 밴드 ３ 단백질 （８２４－８２９） 및／또는 멜라닌세포－자극 호르몬 방출－저해 인자의 용도
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CA2784529C (en) * 2009-12-18 2018-05-22 Catalent France Beinheim Sa Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
KR102201607B1 (ko) * 2012-05-18 2021-01-12 제넨테크, 인크. 고농도 모노클로날 항체 제제
SG11201505607SA (en) 2013-02-28 2015-09-29 Pfizer Enhanced stability of novel liquid compositions
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
JP2017515852A (ja) * 2014-05-16 2017-06-15 ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝障害を処置するための組成物および方法
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins

Also Published As

Publication number Publication date
SG11202110546UA (en) 2021-10-28
US20200323985A1 (en) 2020-10-15
BR112021020287A2 (pt) 2021-12-14
CA3134550A1 (en) 2020-10-15
CA3136485A1 (en) 2020-10-15
MX2021012356A (es) 2021-11-04
CN113784722A (zh) 2021-12-10
KR20210151187A (ko) 2021-12-13
WO2020210722A1 (en) 2020-10-15
CO2021012462A2 (es) 2021-09-30
CO2021014899A2 (es) 2021-11-19
US20220143188A1 (en) 2022-05-12
AR118654A1 (es) 2021-10-20
EA202192792A1 (ru) 2022-01-11
US11185589B2 (en) 2021-11-30
WO2020210723A1 (en) 2020-10-15
SG11202111251SA (en) 2021-11-29
AU2020272059A1 (en) 2021-12-09
MX2021012354A (es) 2021-10-22
JP2022526833A (ja) 2022-05-26
IL287131A (en) 2021-12-01
KR20210151185A (ko) 2021-12-13
EA202192793A1 (ru) 2022-01-12
ZA202108909B (en) 2022-07-27
JP2022526196A (ja) 2022-05-23
EP3952900A1 (en) 2022-02-16
US20220249468A1 (en) 2022-08-11
TW202103726A (zh) 2021-02-01
IL287084A (en) 2021-12-01
CN113966223A (zh) 2022-01-21
EP3952899A1 (en) 2022-02-16
AU2020270985A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
Timper et al. GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function
Guiraud et al. Pharmacological advances for treatment in Duchenne muscular dystrophy
CN106456703A (zh) 铁调素模拟肽及其用途
ES2733639T3 (es) Composiciones de insulina de acción rápida
Bohanon et al. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis
Zappa Villar et al. Intracerebroventricular streptozotocin induces impaired Barnes maze spatial memory and reduces astrocyte branching in the CA1 and CA3 hippocampal regions
ES2441065T3 (es) Uso de la deferiprona y métodos para tratar y/o prevenir la ataxia de Friedreich resultante del mal manejo intracelular de hierro
Yang et al. Small-molecule TrkB agonist 7, 8-dihydroxyflavone reverses cognitive and synaptic plasticity deficits in a rat model of schizophrenia
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
Lau et al. Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium
Ono et al. Imipramine protects mouse hippocampus against tunicamycin-induced cell death
US11534420B2 (en) Compositions and methods for treating cancer
Hooshmandi et al. CEPO-Fc (an EPO derivative) protects hippocampus against Aβ-induced memory deterioration: a behavioral and molecular study in a rat model of Aβ toxicity
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
Podratz et al. Cisplatin induces mitochondrial deficits in Drosophila larval segmental nerve
BR112021018817A2 (pt) Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade
AR108631A1 (es) Formulación de neurotoxinas
Tang et al. Role of silent information regulator 1 in the protective effect of hydrogen sulfide on homocysteine-induced cognitive dysfunction: involving reduction of hippocampal ER stress
KR20200022435A (ko) 펩타이드 조성물 및 관련된 방법
BR112012015016A8 (pt) Formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
Batista et al. The endocannabinoid, endovanilloid and nitrergic systems could interact in the rat dorsolateral periaqueductal gray matter to control anxiety-like behaviors
Kersanté et al. Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area
Duda et al. Spatial working memory in rats: Crucial role of the hippocampus in the allothetic place avoidance alternation task demanding stimuli segregation